跳转至内容
Merck
CN

D9050

N-乙酰基-2,3-脱氢-2-脱氧神经氨酸

≥93% (TLC)

别名:

2,3-脱氢-2-脱氧-N-乙酰神经氨酸

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C11H17NO8
化学文摘社编号:
分子量:
291.25
UNSPSC Code:
12352201
NACRES:
NA.25
PubChem Substance ID:
EC Number:
246-550-7
Beilstein/REAXYS Number:
8722455
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

N-乙酰基-2,3-脱氢-2-脱氧神经氨酸, ≥93% (TLC)

InChI key

JINJZWSZQKHCIP-UFGQHTETSA-N

InChI

1S/C11H17NO8/c1-4(14)12-8-5(15)2-7(11(18)19)20-10(8)9(17)6(16)3-13/h2,5-6,8-10,13,15-17H,3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,8+,9+,10+/m0/s1

SMILES string

CC(=O)N[C@@H]1[C@@H](O)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

biological source

synthetic (organic)

assay

≥93% (TLC)

form

powder

optical activity

[α]20/D 40.8 to 51.0 °, c = 0.66% (w/v) in water

color

white

solubility

H2O: soluble 50 mg/mL, clear, colorless

storage temp.

−20°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

Application

N-乙酰基-2,3-脱氢-2-脱氧神经氨酸(NADNA),一种特异性内源性神经氨酸酶(NEU)抑制剂,可用于研究内源性神经氨酸酶在发育中的作用,在神经过程和通路中的功能,以及其他依赖唾液酸化-脱唾液酸化循环的过程。

Biochem/physiol Actions

细菌、病毒和动物神经氨酸酶(唾液酸酶)的抑制剂。

Other Notes

为了全面了解我们针对客户研究提供的各种单糖产品,建议您访问我们的碳水化合物分类页面。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Santosh Rudrawar et al.
Organic & biomolecular chemistry, 10(43), 8628-8639 (2012-09-15)
Novel 3-C-alkylated-Neu5Ac2en derivatives have been designed to target the expanded active site cavity of influenza virus sialidases with an open 150-loop, currently seen in X-ray crystal structures of influenza A virus group-1 (N1, N4, N5, N8), but not group-2 (N2
Sadagopan Magesh et al.
Bioorganic & medicinal chemistry, 17(13), 4595-4603 (2009-05-20)
Recent advances in the sialidase biology have clarified the role of human sialidases (NEU 1 to NEU4) in the development of various disease states such as cancer, diabetes and arteriosclerosis. Isoform selective human sialidase inhibitors could be a therapeutic tool
Leonard M G Chavas et al.
Journal of medicinal chemistry, 53(7), 2998-3002 (2010-03-13)
With the global spread of the pandemic H1N1 and the ongoing pandemic potential of the H5N1 subtype, the influenza virus represents one of the most alarming viruses spreading worldwide. The influenza virus sialidase is an effective drug target, and a
Wen-Hsien Wen et al.
Bioorganic & medicinal chemistry, 18(11), 4074-4084 (2010-05-11)
Unlike the group-2 neuraminidase, the group-1 neuraminidase of influenza virus possesses a flexible loop (the 150-loop) and a cavity (the 150-cavity) adjacent to the active site, and renders a conformational change from the 'open' form to the 'closed' form on
Amgad Albohy et al.
Bioorganic & medicinal chemistry, 19(9), 2817-2822 (2011-04-15)
The viral neuraminidase enzyme is an established target for anti-influenza pharmaceuticals. However, viral neuraminidase inhibitors could have off-target effects due to interactions with native human neuraminidase enzymes. We report the activity of a series of known inhibitors of the influenza

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持